{"name":"Tesaro, Inc.","slug":"tesaro-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Active comparator: Niraparib","genericName":"Active comparator: Niraparib","slug":"active-comparator-niraparib","indication":"Recurrent ovarian cancer (BRCA-mutated and non-mutated)","status":"phase_3"},{"name":"Dostarlimab (TSR-042)","genericName":"Dostarlimab (TSR-042)","slug":"dostarlimab-tsr-042","indication":"Endometrial cancer, mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H)","status":"phase_3"},{"name":"Placebo matching Niraparib","genericName":"Placebo matching Niraparib","slug":"placebo-matching-niraparib","indication":"Placebo control for ovarian cancer maintenance therapy trials (reference indication for niraparib)","status":"phase_3"},{"name":"Placebo matching dostarlimab","genericName":"Placebo matching dostarlimab","slug":"placebo-matching-dostarlimab","indication":"Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer","status":"phase_3"}]}],"pipeline":[{"name":"Active comparator: Niraparib","genericName":"Active comparator: Niraparib","slug":"active-comparator-niraparib","phase":"phase_3","mechanism":"Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death.","indications":["Recurrent ovarian cancer (BRCA-mutated and non-mutated)","Maintenance treatment of ovarian cancer following platinum-based chemotherapy","HRD-positive ovarian cancer"],"catalyst":""},{"name":"Dostarlimab (TSR-042)","genericName":"Dostarlimab (TSR-042)","slug":"dostarlimab-tsr-042","phase":"phase_3","mechanism":"Dostarlimab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.","indications":["Endometrial cancer, mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H)","Non-small cell lung cancer (in combination with chemotherapy)","Gastric or gastroesophageal junction cancer"],"catalyst":""},{"name":"Placebo matching Niraparib","genericName":"Placebo matching Niraparib","slug":"placebo-matching-niraparib","phase":"phase_3","mechanism":"This is a placebo control arm matching the active drug niraparib, a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes to prevent DNA repair in cancer cells.","indications":["Placebo control for ovarian cancer maintenance therapy trials (reference indication for niraparib)"],"catalyst":""},{"name":"Placebo matching dostarlimab","genericName":"Placebo matching dostarlimab","slug":"placebo-matching-dostarlimab","phase":"phase_3","mechanism":"Dostarlimab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer cells.","indications":["Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer","Recurrent or advanced endometrial cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"bolsamania.com","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - bolsamania.com","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNRlU3TW0tTnBzTnJXMGotTkRzNkFqS2FvclNIZGhldkhUVEJILXFVU1pKOTFjemk5WlBDTEpUQUJxUUtfTlBiREZNcHN6ZncyLXp1eXJqU1lSOW15ek51dWIyTG9mTDlCWGVIMlNCLWVaalAzbTBfVWxORk9ucERjbmVJT2xKY3k4eEowcWl4Q1BSc1NOWFdZbzFsaElZNkpBMEM1Sg?oc=5","date":"2026-01-27","type":"pipeline","source":"BioWorld News","summary":"Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld News","headline":"Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOaXNUMFRRa3lVTkxEXzZVZjYzazlSejJPdTJ2NnJ3NHhQbG5wOTRKdWxwRzFkNVhkTXM2WkVLYlZ0WGllNFVGLVJFSVdzMzM3RFNORmdsRDFGeklOU1plUm9lM3l5bEZ3TzhuWWhZLUE2MWx1SGlXV1ZsNllLUW5tTWJTNHA4bmt2V3hzblRRdWdpNWJXYWtXQi1ZUUFCNjl0dXhXMHJsR0pkQTJicF9EUQ?oc=5","date":"2026-01-20","type":"pipeline","source":"Contract Pharma","summary":"Alteogen, Tesaro Agree to Develop Subcutaneous Form of Dostarlimab - Contract Pharma","headline":"Alteogen, Tesaro Agree to Develop Subcutaneous Form of Dostarlimab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNT0ltSTFGbXhTbGNidTRwOUxKbmFXOWFDYUFRWXdDSWRCXzJNWUlDLTlVUTN5cXl2R3UxajhxdnRxVFIxRm9QSU1POWxWUHJkTnMtYVhvWXdlUHpJRHBOaXVlRTV4Q0taemFyZVo0SGJBZFJnQ1Fob0JVSHctMVV3ZjRoaHMyMFRWRE9Xd3FKQ1RKX0NwajFwR0F3Zw?oc=5","date":"2026-01-20","type":"pipeline","source":"The Pharma Letter","summary":"Alteogen grants GSK’s Tesaro global rights to ALT-B4 - The Pharma Letter","headline":"Alteogen grants GSK’s Tesaro global rights to ALT-B4","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPQ0tzNURrdzR4emk2elBjTndDaVg1Qk5OdXBsVERuQnhzV1BBaW5rWXdJVG5INWh3Y1JwY3F4VTA2Um43d1VvTlAydzdMbkxaM1B1dmlRZUVJS3N0elAyT0ZRRHRZMWpvM2hVNG1pV1NZYzlpTnB1ajFWTG9rQUtuRHN6QmxuQS1icmtRVDdnVFV4UkViOTZTc0hqQlY?oc=5","date":"2025-11-24","type":"pipeline","source":"Pharmaceutical Executive","summary":"Tesaro and AnaptysBio's Legal Battle | PharmExec - Pharmaceutical Executive","headline":"Tesaro and AnaptysBio's Legal Battle | PharmExec","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPNXQwdTEtQ3BWTW9tUG5NczMyYTVuTThiV2I0emduaGRXZ2hHakhtcWZxWGhka2pDencweWVxcUEwdzFfWEQ4NDZoVjlBX3RvLXVjZnZBVkh0Zk1Mb05OdU5jUFhjcXBSR2JFeTE2OFA0c1pvRzNabm9FM0ZxaEdjSTluNjRVNWFzVzIxbm5pTXY3dmZtQ0JNWFg5ZTJRV0hEWFdfRzZOSmwtaWdCQzVvcVJxc2tUek1uczloa2EwMXFIYTJRdmM2UXc5cDVRTDNSYzNUQ0dtTlFOcDhRdmlzeXJn?oc=5","date":"2025-11-21","type":"deal","source":"Reuters","summary":"AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters","headline":"AnaptysBio shares tumble after legal fight with GSK over cancer drug license","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPdXFHMnlpX3BabF9tZlVZLWQtWXlGdnRUb1VrSnlmNi12ZXQzUmUwck12Nm9MS1hjRkZlQzdvcjVIMGJCR3RGMEJvenRncERLRGFEd3FHQXhVYzllVFNmbXN1M2Zfd3M4MHB4aGJFTHJYdFZFQ1YzcWtkWl81eUJjQ0tNSXRlOFhCMk5uNkQ1Vnh6eVVlcWJYVHE4dHNPdmdhMi1OT2U5OE5pQWY1TEdfYXNn?oc=5","date":"2025-11-21","type":"pipeline","source":"Fierce Pharma","summary":"GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement - Fierce Pharma","headline":"GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQZXZwRk9oMUFleGpMNzEyNzNCQ3ZiWmhSWEhQcktrNmM0YW9NaXAxVWZROGJMNlpqbnJZeVc3WnZ0QzZlZjhnTm9KYlduc2NkMXA3SEJtOWViVDMtR1JyeW5aWXIzdEFGNVYzSXo2NFFuUDFucEZoa2FZN3J1Wm5hNG1rVWtPZzBLaUNHeUhR?oc=5","date":"2025-11-21","type":"earnings","source":"BioPharma Dive","summary":"GSK, Anaptysbio sue each other over Jemperli revenue - BioPharma Dive","headline":"GSK, Anaptysbio sue each other over Jemperli revenue","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-21","type":"pipeline","source":"Medical Dialogues","summary":"GSK arm Tesaro initiates litigation against AnaptysBio - Medical Dialogues","headline":"GSK arm Tesaro initiates litigation against AnaptysBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1KWUxUQjdRYnRSX3hZYXg4ZXI2bDR5Z0xvdzJ3WWJjd3paTk9GVk9qa0tZb0M5SkFoZ0NxM1Jsa1NOQ3NXdEt2a3JXMzV4bTd0NTcxSURncW85UUdTQ1B1QW4wZnVzUU4xazZvLXQxdmE?oc=5","date":"2019-01-23","type":"deal","source":"PharmaTimes","summary":"GSK completes Tesaro deal - PharmaTimes","headline":"GSK completes Tesaro deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOX0RBVmx4OXl0VnI1cDJ2RTMzZ1NDcFNVNTBkU3VkUXQ2NE82Y0lpZDVwS0Ytdm9OeGJCTzJ6Ylpaa2xJVkJVTzJtV2d2SUkzRUw2c2dtdW5reFBndnQ5N3BhVkpSa1BMVzhEODJlYlJFNmNMaUxpMDctODFfS2dPRUppNEd1MWptcXJXWHpEV0lHS3BoMUd1amxteUtrMzgxZE80UHh1MGFKc1VJNnlyUDZQSjEwR2tkZlpwcFpndG15NFpLU0Vlcg?oc=5","date":"2019-01-22","type":"pipeline","source":"GSK","summary":"GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company - GSK","headline":"GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQc1NMdGIyQXo1Z0tITDRzdWpzdGlNRldWNWRWbFlIclpieFU1Vl9IV3lUbDRoMmxsdGx1LW4xTVNUTkZ0OXdhU1MtYUZNN21hbXU1RHV2SW1UaHVlS0o5WldPSFhBVWZZUjJkbkNMcXNaQzA0cWliV3Z4TkN4WmlfVG93eUw4dktiVnc?oc=5","date":"2018-12-03","type":"deal","source":"GSK","summary":"Agreement to acquire TESARO - GSK","headline":"Agreement to acquire TESARO","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}